PRECLINICAL ALZHEIMER'S DISEASE
Clinical trials for PRECLINICAL ALZHEIMER'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new PRECLINICAL ALZHEIMER'S DISEASE trials appear
Sign up with your email to follow new studies for PRECLINICAL ALZHEIMER'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a vaccine stop Alzheimer's before symptoms start?
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage study tests a new vaccine called AV-1980R in 48 adults aged 65-80 who have early signs of Alzheimer's in their blood but no memory problems yet. The vaccine targets a protein called tau, which is linked to Alzheimer's damage. The main goal is to check if the vacc…
Matched conditions: PRECLINICAL ALZHEIMER'S DISEASE
Phase: PHASE1 • Sponsor: Institute for Molecular Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 08:06 UTC
-
New vaccine aims to halt Alzheimer's brain tangles
Disease control Not yet recruitingThis study tests a treatment called AADvac1, which targets tau protein tangles in the brain, a hallmark of Alzheimer's. It will be given alone or with another drug (donanemab) to 450 adults aged 50-80 with early-stage Alzheimer's. The goal is to see if it safely reduces tau build…
Matched conditions: PRECLINICAL ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated May 26, 2026 08:12 UTC
-
Major trial takes on Alzheimer's tau tangles with multiple drugs
Disease control Not yet recruitingThis study tests whether new drugs that target tau protein in the brain can slow or stop Alzheimer's disease in its early stages. About 900 adults aged 50 to 80 with very mild or no symptoms will receive a tau drug, a combination of a tau drug and donanemab, or donanemab alone. T…
Matched conditions: PRECLINICAL ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated May 26, 2026 08:11 UTC